Clinical Trial

Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer

Study acronym: JCOG1801
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 4, 2020 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
JCOG1801 is a randomized phase III trial which was initiated in Japan in August 2019 to confirm the superiority of preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for local relapse-free survival over standard treatment, i.e. surgery plus adjuvant chemotherapy, for previously non-irradiated locally recurrent rectal cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-02-26.
Trial Details
NCT Number NCT04288999
Lead Sponsor National Cancer Center Hospital East
Collaborators: Japan Clinical Oncology Group, Japan Agency for Medical Research and Development
Conditions Rectal Cancer Recurrent
Enrollment 110 participants
Start Date 2019-10-01
Primary Completion 2025-08 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2020-06-04